MindMaze reports home — based MindMotion rehab program triples weekly motor — training dose in real — world study
MindMaze Therapeutics disclosed new real-world evidence on home-based neurorehabilitation from a multi-site program with Vibra Healthcare. Results were presented on Oct. 13 at the American Congress of Rehabilitation Medicine in Washington. Home use of MindMotion lifted overall rehabilitation intensity versus outpatient therapy alone, with most training completed without direct supervision. Participants recorded broad functional gains, supporting a strategy to extend neurorehabilitation beyond clinics into the home. Findings set up the planned year-end 2026 launch of MindMotion Lite, a tablet-based version intended to simplify home deployment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindMaze Therapeutics Holding SA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2415188_en) on October 14, 2026, and is solely responsible for the information contained therein. (C) Copyrigh
MindMaze Therapeutics disclosed new real-world evidence on home-based neurorehabilitation from a multi-site program with Vibra Healthcare. Results were presented on Oct. 13 at the American Congress of Rehabilitation Medicine in Washington. Home use of MindMotion lifted overall rehabilitation intensity versus outpatient therapy alone, with most training completed without direct supervision.
Participants recorded broad functional gains, supporting a strategy to extend neurorehabilitation beyond clinics into the home. Findings set up the planned year-end 2026 launch of MindMotion Lite, a tablet-based version intended to simplify home deployment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.
MindMaze Therapeutics Holding SA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2415188_en) on October 14, 2026, and is solely responsible for the information contained therein. (C)